Sutro Biopharma (STRO) Accumulated Expenses (2017 - 2026)

Sutro Biopharma has reported Accumulated Expenses for 9 years, with the latest figure at $12.6 million in Q4 2025.

• Quarterly Accumulated Expenses fell 2.38% year-over-year to $12.6 million in Q4 2025, while the trailing twelve-month figure through Dec 2025 was $12.6 million (down 2.38% YoY) and the FY2025 annual result came in at $12.6 million, down 2.38% from the prior year.
• Accumulated Expenses eased to $12.6 million in Q4 2025 per STRO's latest filing, from $34.7 million in the prior quarter.
• Over five years, Accumulated Expenses peaked at $38.5 million in Q4 2023 and troughed at $4.5 million in Q1 2021.
• A 5-year average of $13.2 million and a median of $11.5 million in 2021 frame the typical range for Accumulated Expenses.
• The sharpest annual moves came in 2024 and 2025: Accumulated Expenses sank 66.46% in 2024, then jumped 163.16% in 2025.
• Over 5 years, Accumulated Expenses stood at $11.4 million in 2021, then gained by 29.32% to $14.8 million in 2022, then surged by 160.59% to $38.5 million in 2023, then tumbled by 66.46% to $12.9 million in 2024, then declined by 2.38% to $12.6 million in 2025.
• According to Business Quant data, Accumulated Expenses over the past three periods registered $12.6 million, $34.7 million, and $11.8 million for Q4 2025, Q3 2025, and Q2 2025 respectively.